Implant Therapy Articles & Analysis
16 news found
The procedure marks the first U.S. patient implant in Synchron’s COMMAND trial, which is being conducted under the first investigational device exemption (IDE) awarded by the FDA to a company assessing a permanently implanted BCI. ...
I am eager to bring my experience to Synchron to help support its mission of developing an endovascular implant that can transfer information from every corner of the brain at ...
“Our recent results presented at the American Academy of Neurology Conference 2022 show that our permanent BCI implant is safe, and can improve independence and quality of life for those living with ...
The device also stayed in place for all four patients and the blood vessel in which the device was implanted remained open. Following implantation in the SWITCH clinical trial, patients were able to use the Stentrode system unsupervised in their homes to send text messages, conduct online shopping and manage their finances. About the Stentrode Synchron’s ...
Four Patients With ALS Who Received Stentrode™ Implant Gained Ability to Perform Daily Online Tasks No Serious Adverse Events Reported after 12 Months Synchron, a brain computer interface (BCI) company, today announced the results from a study in which four people with ALS received an implant of Synchron’s Stentrode™ device, a ...
Synchron is the only company to receive FDA approval to conduct clinical trials of a permanently implanted BCI. The company’s novel BCI technology leverages the blood vessels as the natural highways to the brain. ...
Clinical trials of the device in patients with DRE have shown impressive results comparable to those achieved with adjunctive pharmaceutical and implantable device therapies,” commented Dr. Colin Kealey, President of NeuroSigma. “This Breakthrough Device Designation will expedite completion of a pivotal trial of external trigeminal nerve stimulation ...
Statistically significant and clinically meaningful mean change in diurnal IOP at 12 and 26 weeks (p<0.001). Implant persistence through a minimum of 21 weeks with full implant biodegradation by week 40, over a 4-6 week period. Low dose implant shown to be generally well tolerated with no ocular serious adverse events related to product, no ...
The Promaxo system reinforces our practice goals as it not only allows us to refine our biopsies, but also facilitates MR-guided therapies within the comfort of our offices and ambulatory surgery center. ...
Synchron, a brain computer interface company, today announced a Twitter takeover by Philip O’Keefe, one of the patients implanted with the Stentrode brain computer interface. Mr. O’Keefe is the first person to successfully message the world on social media directly through thought using an implantable brain computer interface. ...
Procedure removes risk of kidney injury or complications in patients with advanced kidney disease or allergy to contrast dye On Sept. 30, CentraCare completed the world’s first contrast-free WATCHMAN implant using 4D holographic therapy guidance, developed by EchoPixel, as the alternative imaging modality. ...
Mehee Choi, director of Medical Affairs at GT Medical Technologies, will discuss new data in patients with recurrent glioblastoma (GBM), and access-to-care for patients with resectable brain tumors. GammaTile is an implantable radiation therapy consisting of bioresorbable collagen tiles embedded with Cesium-131 sources provided by Isoray, Inc. ...
Patients begin using the device at home soon after implantation and may wirelessly control external devices by thinking about moving their limbs. ...
Alleviant Medical Inc., a privately-held medical device company, today announced that the US Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its transcatheter technology. The technology offers a no-implant interatrial shunt therapy for patients suffering from heart failure with preserved (HFpEF) and mid-range ...
Justin Beyers will be presenting at CSM 2018 on a poster titled: “Effects of Therapeutic Ultrasound on the Stability of Cemented Simulated Implants. The poster authored by Dr. Peter Bonutti, Justin Beyers, Tonya Bierman, Matt Cremens, and Nicole Tipsword explores the effect of therapeutic ultrasound on cemented implants. The American Physical ...
In December 2016, the first patient was implanted in the trial, and she continues to receive the therapy today. ...